Table 1

Clinical characteristics of the 106 patients who recovered from COVID-19

Female, n (%)56 (52.8)
Age, years (IQR)48.3 (33–62)
Non-smokers, n (%)61 (57.5)
Presence of any comorbidities, n (%)45 (42.5)
Types of comorbidities
 Hypertension18 (17.0)
 Diabetes mellitus16 (15.1)
 Hyperlipidaemia12 (11.3)
Length of stay in hospital, days (IQR)17 (10–25)
Severity of COVID-19, n (%)
 Asymptomatic4 (3.8)
 Mild31 (29.2)
 Moderate55 (51.9)
 Severe10 (9.4)
 Critical6 (5.7)
Treatments for COVID-19, n (%)
 Lopinavir/ritonavir56 (52.8)
 Ribavirin30 (28.3)
 Interferon39 (36.8)
 Remdesivir6 (5.7)
 Antibiotics25 (23.6)
Number of persistent symptoms by 3 months, n (%)86 (81.1)
 121 (19.8)
 2–326 (24.5)
 >339 (36.8)
Number of persistent symptoms by 6 months, n (%)81 (76.4)
 117 (16.0)
 2–329 (27.4)
 >335 (33.0)